D.C. Update: Prescription Drug Pricing and Advertising
ANA’s Government Relations team provided a history of direct-to-consumer pharmaceutical advertising in the U.S. and discussed legislative challenges that pharmaceutical companies might face during the 2017 session of Congress.
This Is an ANA Member Exclusive
Access to this item is reserved for ANA members only.
Log in
Already have an account? The industry's best insights and resources await:
No Account?
Use your business email address to create your free account; if you're a member through your company, we'll know.
Members can access their benefits as soon as they sign up and log in.
Not a Member?
You can still create a free account to access the latest from our online publication, ANA Magazine, receive content and special event offers through our newsletters, get breaking industry updates, and so much more.
The content you're trying to see is available to:
- ANA Client-Side Marketer Tier Members
- Platinum Tier Members
- Gold Tier Members
- Silver Tier Members
- Individual Members
Discover everything the ANA can do to help drive growth for your organization. Connect with our membership team.